Histomolecular Profiling in Small-Bowel Diseases

ClinicalTrials.gov ID

NCT07556328

Lead Sponsor

Tampere University HospitalOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

300Estimated

Last Update Posted

Apr 29, 2026Actual

Start Date

Nov 1, 2025Actual

Primary Completion Date

Dec 31, 2035Estimated

Completion Date

Dec 31, 2035Estimated

Official Title

Histological and Molecular Profiling in the Diagnostics and Treatment of Small-Bowel Diseases - A Prospective Cohort Study (The DeepBowel Study)

Brief Summary

This prospective cohort study aims to establish reliable histological reference values for normal small-bowel mucosa, improve histological diagnostic quality in celiac disease, and develop an advanced molecular profile for disease diagnosis and treatment response evaluation. The study will collect duodenal biopsies from three groups: healthy controls undergoing clinically indicated gastroscopy, patients referred for primary celiac disease diagnostics, and patients with small-bowel mucosal injury unresponsive to a gluten-free diet. Patients will undergo routine clinical assessment via standard pathology review of diagnostic biopsies. Biopsies will be analyzed using digital morphometry, AI-based image analysis, RNA sequencing (transcriptomics), and intestinal organoid cultures.

Detailed Description

Celiac disease is a chronic autoimmune condition affecting approximately 2.4% of the Finnish population. Despite advances in diagnostics, histological assessment of duodenal biopsies remains the gold standard for diagnosis in most cases. However, histological evaluation is subject to inter-observer variability, with a 10% diagnostic error rate reported in international multicenter studies.

This study will:

1. Establish reliable digital morphometric reference values (villus-to-crypt ratio) for normal small-bowel mucosa using digitized biopsy slides and AI/machine-learning-based analysis tools;
2. Investigate molecular pathways underlying celiac disease progression and treatment response through RNA sequencing (RNA-Seq transcriptomics) of biopsies from celiac disease patients and healthy controls, with a reference comparison to a drug-trial dataset;
3. Model disease progression and refractory small-bowel injury using intestinal organoid cultures derived from biopsies of celiac patients, refractory patients, and healthy controls.

Research biopsy samples will be processed at the Tampere University Celiac Disease Research Center under pseudonymization. Statistical analyses will be done in collaboration with the study statistician. All data will be stored for 15 years following study completion.

• Celiac Disease
• Small Bowel Disease
• Refractory Celiac Disease

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

• Age ≥ 18 years
• Clinically indicated upper gastrointestinal endoscopy (gastroscopy)
• Written informed consent obtained prior to procedure
• For Group 1 (Healthy Controls): Negative celiac disease antibodies (anti-transglutaminase and/or anti-endomysium); no suspected celiac
• For Group 2 (Celiac Diagnostics): Referred for primary celiac disease diagnostics requiring duodenal biopsy
• For Group 3 (Refractory Injury): Confirmed small-bowel mucosal injury not responsive to a gluten-free diet

Exclusion Criteria:

• For Group 1 (Healthy Controls): Other small-bowel diseases causing mucosal injury, including Crohn's disease and small-bowel ulcers
• Inability to provide written informed consent
• Refusal to participate

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Tampere University HospitalOTHER

Collaborators

Tampere UniversityOTHER

juha.taavela@tuni.fi+358443400330

juha.taavela@otuni.fi+358443400330

• Small Bowel Ultrasound and Antibody Levels in Celiac Disease Activity

  NCT07453589

  Not yet recruitingObservationalUpdated Mar 6, 2026
• Precision Diagnostics of Functional and Organic Intestinal Pathology Based on Cellular and Molecular Profiling

  NCT05277662

  Unknown statusInterventionalNot ApplicableUpdated Mar 14, 2022
• Exploratory Study of Rectal Mucus for Diagnosing Disease

  NCT04659590

  CompletedObservationalUpdated Oct 18, 2024
• AI System for Detection and Characterization of Chronic Enteropathies

  NCT07387185

  RecruitingObservationalUpdated Feb 4, 2026
• Local and Systemic Immunoprofiling of Patients Diagnosed With Ulcerative Colitis

  NCT05680883

  Unknown statusObservationalUpdated Jan 11, 2023
• Improved Diagnostics of Celiac Disease in Children

  NCT02072590

  CompletedObservationalUpdated Nov 24, 2023